1
|
Stefanopoulou E, Grunfeld EA. Mind-body interventions for vasomotor symptoms in healthy menopausal women and breast cancer survivors. A systematic review. J Psychosom Obstet Gynaecol 2017; 38:210-225. [PMID: 27832718 DOI: 10.1080/0167482x.2016.1235147] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
Mind-body therapies are commonly recommended to treat vasomotor symptoms, such as hot flushes and night sweats (HFNS). The purpose of this systematic review was to evaluate the available evidence to date for the efficacy of different mind-body therapies to alleviate HFNS in healthy menopausal women and breast cancer survivors. Randomized controlled trials (RCTs) were identified using seven electronic search engines, direct searches of specific journals and backwards searches through reference lists of related publications. Outcome measures included HFNS frequency and/or severity or self-reported problem rating at post-treatment. The methodological quality of all studies was systematically assessed using predefined criteria. Twenty-six RCTs met the inclusion criteria. Interventions included yoga (n = 5), hypnosis (n = 3), mindfulness (n = 2), relaxation (n = 7), paced breathing (n = 4), reflexology (n = 1) and cognitive behavioural therapy (CBT) (n = 4). Findings were consistent for the effectiveness of CBT and relaxation therapies for alleviating troublesome vasomotor symptoms. For the remaining interventions, although some trials indicated beneficial effects (within groups) at post-treatment and/or follow up, between group findings were mixed and overall, methodological differences across studies failed to provide convincing supporting evidence. Collectively, findings suggest that interventions that include breathing and relaxation techniques, as well as CBT, can be beneficial for alleviating vasomotor symptoms. Additional large, methodologically rigorous trials are needed to establish the efficacy of interventions on vasomotor symptoms, examine long-term outcomes and understand how they work.
Collapse
Affiliation(s)
- Evgenia Stefanopoulou
- a Section of Health Psychology, Institute of Psychiatry, Psychology and Neuroscience , King's College London , London , UK
| | - Elizabeth Alice Grunfeld
- b Centre for Technology Enabled Health Research, Faculty of Health and Life Sciences , Coventry University , Coventry , UK
| |
Collapse
|
2
|
Affiliation(s)
- Susan Bauer-Wu
- Phyllis F. Cantor Center Research in Nursing and Patient Care Services Dana-Farber Cancer Institute and Harvard Medical School 44 Binney Street, G-121 Boston, MA 02115,
| |
Collapse
|
3
|
Hutton B, Yazdi F, Bordeleau L, Morgan S, Cameron C, Kanji S, Fergusson D, Tricco A, Straus S, Skidmore B, Hersi M, Pratt M, Mazzarello S, Brouwers M, Moher D, Clemons M. Comparison of physical interventions, behavioral interventions, natural health products, and pharmacologics to manage hot flashes in patients with breast or prostate cancer: protocol for a systematic review incorporating network meta-analyses. Syst Rev 2015; 4:114. [PMID: 26307105 PMCID: PMC4549873 DOI: 10.1186/s13643-015-0099-y] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2015] [Accepted: 08/12/2015] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Breast and prostate cancers are the most commonly diagnosed non-dermatologic malignancies in Canada. Agents including endocrine therapies (e.g., aromatase inhibitors, gonadotrophin-releasing hormone analogs, anti-androgens, tamoxifen) and chemotherapy have improved survival for both conditions. As endocrine manipulation is a mainstay of treatment, it is not surprising that hot flashes are a common and troublesome adverse effect. Hot flashes can cause chills, night sweats, anxiety, and insomnia, lessening patients' quality of life. These symptoms impact treatment adherence, worsening prognosis. While short-term estrogen replacement therapy is frequently used to manage hot flashes in healthy menopausal women, its use is contraindicated in breast cancer. Similarly, testosterone replacement therapy is contraindicated in prostate cancer. It is therefore not surprising that non-hormonal pharmacological treatments (anti-depressants, anti-epilectics, anti-hypertensives), physical/behavioral treatments (e.g., acupuncture, yoga/exercise, relaxation techniques, cognitive behavioral therapy), and natural health products (e.g., black cohosh, flax, vitamin E, ginseng) have been studied for control of hot flashes. There is a need to identify which interventions minimize the frequency and severity of hot flashes and their impact on quality of life. This systematic review and network meta-analysis of randomized studies will synthesize available evidence addressing this knowledge gap. METHODS/DESIGN An electronic search of Medline, Embase, AMED, PsycINFO, and the Cochrane Register of Controlled Trials has been designed by an information specialist and peer reviewed by a second information specialist. Study selection and data collection will be performed by two reviewers independently. Risk of bias assessments will be completed using the Cochrane Risk of Bias Scale. Outcomes of interest will include validated measures of hot flash severity, hot flash frequency, quality of life, and harms. Bayesian network meta-analyses will be performed where judged appropriate based on review of clinical and methodologic features of included studies. DISCUSSION Our review will include a broad range of interventions that patients with breast and prostate cancer have attempted to use to manage hot flashes. Our work will establish the extent of evidence underlying these interventions and will employ an inclusive approach to analysis to inform comparisons between them. Our findings will be shared with Cancer Care Ontario for consideration in the development of guidance related to supportive care in these patients. SYSTEMATIC REVIEW REGISTRATION PROSPERO CRD42015024286.
Collapse
Affiliation(s)
- Brian Hutton
- Ottawa Hospital Research Institute, Ottawa, Canada.
- University of Ottawa School of Epidemiology, Public Health and Preventive Medicine, Ottawa, Canada.
| | | | - Louise Bordeleau
- Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
| | - Scott Morgan
- Division of Radiation Oncology, Department of Radiology, University of Ottawa, Ottawa, Canada.
| | | | | | - Dean Fergusson
- Ottawa Hospital Research Institute, Ottawa, Canada.
- University of Ottawa School of Epidemiology, Public Health and Preventive Medicine, Ottawa, Canada.
| | - Andrea Tricco
- Li Ka Shing Knowledge Institute, St Mike's Hospital, Toronto, Canada.
| | - Sharon Straus
- Li Ka Shing Knowledge Institute, St Mike's Hospital, Toronto, Canada.
| | | | - Mona Hersi
- Ottawa Hospital Research Institute, Ottawa, Canada.
| | - Misty Pratt
- Ottawa Hospital Research Institute, Ottawa, Canada.
| | - Sasha Mazzarello
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, Ottawa, Canada.
| | - Melissa Brouwers
- Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
| | - David Moher
- Ottawa Hospital Research Institute, Ottawa, Canada.
- University of Ottawa School of Epidemiology, Public Health and Preventive Medicine, Ottawa, Canada.
| | - Mark Clemons
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, Ottawa, Canada.
| |
Collapse
|
4
|
Dueregger A, Heidegger I, Ofer P, Perktold B, Ramoner R, Klocker H, Eder IE. The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment. Nutrients 2014; 6:4491-519. [PMID: 25338271 PMCID: PMC4210931 DOI: 10.3390/nu6104491] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2014] [Revised: 09/07/2014] [Accepted: 09/19/2014] [Indexed: 01/17/2023] Open
Abstract
Prostate cancer (PCa), the most commonly diagnosed cancer and second leading cause of male cancer death in Western societies, is typically androgen-dependent, a characteristic that underlies the rationale of androgen deprivation therapy (ADT). Approximately 90% of patients initially respond to ADT strategies, however many experience side effects including hot flashes, cardiotoxicity, metabolic and musculoskeletal alterations. This review summarizes pre-clinical and clinical studies investigating the ability of dietary supplements to alleviate adverse effects arising from ADT. In particular, we focus on herbal compounds, phytoestrogens, selenium (Se), fatty acids (FA), calcium, and Vitamins D and E. Indeed, there is some evidence that calcium and Vitamin D can prevent the development of osteoporosis during ADT. On the other hand, caution should be taken with the antioxidants Se and Vitamin E until the basis underlying their respective association with type 2 diabetes mellitus and PCa tumor development has been clarified. However, many other promising supplements have not yet been subjected large-scale clinical trials making it difficult to assess their efficacy. Given the demographic trend of increased PCa diagnoses and dependence on ADT as a major therapeutic strategy, further studies are required to objectively evaluate these supplements as adjuvant for PCa patients receiving ADT.
Collapse
Affiliation(s)
- Andrea Dueregger
- Division of Experimental Urology, Department of Urology, Innsbruck Medical University, Innsbruck, A-6020 Austria.
| | - Isabel Heidegger
- Division of Experimental Urology, Department of Urology, Innsbruck Medical University, Innsbruck, A-6020 Austria.
| | - Philipp Ofer
- Division of Experimental Urology, Department of Urology, Innsbruck Medical University, Innsbruck, A-6020 Austria.
| | - Bernhard Perktold
- Department of Dietetics, University of Applied Sciences Tyrol, Innsbruck A-6020, Austria.
| | - Reinhold Ramoner
- Department of Dietetics, University of Applied Sciences Tyrol, Innsbruck A-6020, Austria.
| | - Helmut Klocker
- Division of Experimental Urology, Department of Urology, Innsbruck Medical University, Innsbruck, A-6020 Austria.
| | - Iris E Eder
- Division of Experimental Urology, Department of Urology, Innsbruck Medical University, Innsbruck, A-6020 Austria.
| |
Collapse
|
5
|
Ulbricht C, Windsor RC. An Evidence-Based Systematic Review of Black cohosh (Cimicifuga racemosa, Actaea racemosa) by the Natural Standard Research Collaboration. J Diet Suppl 2014; 12:265-358. [PMID: 25153652 DOI: 10.3109/19390211.2014.946731] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
An evidence-based systematic review of black cohosh (Cimicifuga racemosa, Actaea racemosa) by the Natural Standard Research Collaboration consolidates the safety and efficacy data available in the scientific literature using a validated, reproducible grading rationale. This article includes written and statistical analysis of clinical trials, plus a compilation of expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing.
Collapse
|
6
|
Banu J. Causes, consequences, and treatment of osteoporosis in men. DRUG DESIGN DEVELOPMENT AND THERAPY 2013; 7:849-60. [PMID: 24009413 PMCID: PMC3758213 DOI: 10.2147/dddt.s46101] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Men undergo gradual bone loss with aging, resulting in fragile bones. It is estimated that one in five men will suffer an osteoporotic fracture during their lifetime. The prognosis for men after a hip fracture is very grim. A major cause is reduction of free testosterone. Many other factors result in secondary osteoporosis, including treatment for other diseases such as cancer and diabetes. Patients should be screened not only for bone density but also assessed for their nutritional status, physical activity, and drug intake. Therapy should be chosen based on the type of osteoporosis. Available therapies include testosterone replacement, bisphosphonates, and nutritional supplementation with calcium, vitamin D, fatty acids, and isoflavones, as well as certain specific antibodies, like denosumab and odanacatib, and inhibitors of certain proteins.
Collapse
Affiliation(s)
- Jameela Banu
- Coordinated Program in Dietetics, College of Health Sciences and Human Services and Department of Biology, College of Science and Mathematics, University of Texas-Pan American, Edinburg, TX 78539, USA.
| |
Collapse
|
7
|
Trost LW, Serefoglu E, Gokce A, Linder BJ, Sartor AO, Hellstrom WJG. Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement. J Sex Med 2013; 10 Suppl 1:84-101. [PMID: 23387914 DOI: 10.1111/jsm.12036] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
INTRODUCTION Androgen deprivation therapy (ADT) is commonly utilized in the management of both localized and advanced adenocarcinoma of the prostate. The use of ADT is associated with several adverse events, physical changes, and development of medical comorbidities/mortality. AIM The current article reviews known adverse events associated with ADT as well as treatment options, where available. Current recommendations and guidelines are cited for ongoing monitoring of patients receiving ADT. METHODS A PubMed search of topics relating to ADT and adverse outcomes was performed, with select articles highlighted and reviewed based on level of evidence and overall contribution. MAIN OUTCOME MEASURES Reported outcomes of studies detailing adverse effects of ADT were reviewed and discussed. Where available, randomized trials and meta-analyses were reported. RESULTS ADT may result in several adverse events including decreased libido, erectile dysfunction, vasomotor symptoms, cognitive, psychological and quality of life impairments, weight gain, sarcopenia, increased adiposity, gynecomastia, reduced penile/testicular size, hair changes, periodontal disease, osteoporosis, increased fracture risk, diabetes and insulin resistance, hyperlipidemia, and anemia. The definitive impact of ADT on lipid profiles, cardiovascular morbidity/mortality, and all-cause mortality is currently unknown with available data. Treatment options to reduce ADT-related adverse events include changing to an intermittent treatment schedule, biophysical therapy, counseling, and pharmacotherapy. CONCLUSIONS Patients treated with ADT are at increased risk of several adverse events and should be routinely monitored for the development of potentially significant morbidity/mortality. Where appropriate, physicians should reduce known risk factors and counsel patients as to known risks and benefits of therapy.
Collapse
|
8
|
Vandecasteele K, Ost P, Oosterlinck W, Fonteyne V, De Neve W, De Meerleer G. Evaluation of the Efficacy and Safety of Salvia officinalis
in Controlling Hot Flashes in Prostate Cancer Patients Treated with Androgen Deprivation. Phytother Res 2011; 26:208-13. [DOI: 10.1002/ptr.3528] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2010] [Revised: 03/29/2011] [Accepted: 03/30/2011] [Indexed: 12/12/2022]
Affiliation(s)
| | - Piet Ost
- Department of Radiation Oncology; Ghent University Hospital; Ghent Belgium
| | | | - Valérie Fonteyne
- Department of Radiation Oncology; Ghent University Hospital; Ghent Belgium
| | - Wilfried De Neve
- Department of Radiation Oncology; Ghent University Hospital; Ghent Belgium
| | - Gert De Meerleer
- Department of Radiation Oncology; Ghent University Hospital; Ghent Belgium
| |
Collapse
|
9
|
Andrikoula M, Baker D, Nesic J, Liao LM, Duka T, Prelevic GM. The effects of micronutrient supplementation on vasomotor symptoms in postmenopausal women. Climacteric 2011; 14:544-50. [DOI: 10.3109/13697137.2011.558951] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
10
|
Managing hot flushes in men after prostate cancer--a systematic review. Maturitas 2009; 65:15-22. [PMID: 19962840 DOI: 10.1016/j.maturitas.2009.10.017] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2009] [Revised: 10/27/2009] [Accepted: 10/27/2009] [Indexed: 12/21/2022]
Abstract
CONTEXT AND OBJECTIVE The aim of this study was to describe hot flushes in men with prostate cancer, and their treatment methods. METHOD A systematic review was conducted of the literature indexed between 1966 and 2009 on the MEDLINE, the ISI Web of Knowledge, Cinahl and PsycINFO. Of 252 articles identified, 32 were selected for consideration of their complete texts, of which five were subject to detailed analysis. RESULTS Diethylstilbestrol, megestrol acetate and cyproterone acetate have the strongest effect, giving a 75% or larger decrease of the number of hot flushes, but they may have severe or bothersome side-effects. Gabapentin has an uncertain effect. Clonidine is not proven effective for hot flushes. Long-term effects were not evaluated in any of the studies. SSRI/SNRI and acupuncture may have a moderate effect on hot flushes but are not proven in any RCTs. CONCLUSION Hot flushes are common and bothersome symptoms in men with prostate cancer and those taking anti-androgen treatment, and reduce quality of life. Few treatments are available and some are avoided for these patients. Additional prospective treatment studies are needed, with long-term follow-up, in order to evaluate the effects and risks of treatments. Treatments with few or no severe side-effects should be prioritised in future investigations. Experimental studies are also needed to elucidate the mechanism behind hot flushes in men and to suggest routes for the development of new treatments.
Collapse
|
11
|
Irani J, Salomon L, Oba R, Bouchard P, Mottet N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 2009; 11:147-54. [PMID: 19963436 DOI: 10.1016/s1470-2045(09)70338-9] [Citation(s) in RCA: 84] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Hot flushes are the most common complaints reported by men undergoing androgen suppression treatment for prostate cancer. We designed a randomised double-blind trial to compare the efficacy of three drugs, each of which has proven effective for preventing hot flushes in previous studies. METHODS Men with prostate cancer with an indication for androgen suppression were enrolled in the study at 106 urology centres in France between April 14, 2004, and April 20, 2007. All patients were treated for 6 months with leuprorelin (11.25 mg). At month 6, patients who spontaneously asked for treatment, or those who presented with 14 hot flushes or more during the week before the visit, were randomly assigned to either venlafaxine 75 mg daily, medroxyprogesterone acetate 20 mg daily, or cyproterone acetate 100 mg daily. All patients received two indistinguishable pills in the morning and one in the evening from week 1 to week 8, and one indistinguishable pill in the morning from week 9 to week 10, to comply with the double-blind design. Random assignment with a block size of three was done centrally, by fax, and each patient was given a randomisation number. The allocation sequence was stratified by centre. Assessment was done at inclusion, at randomisation, and then at 4 weeks, 8 weeks, and 12 weeks after randomisation. Participants completed a daily hot-flush diary for 1 week, and a quality of life questionnaire before each visit throughout the study. The primary outcome was the change in median daily hot-flush score between randomisation and 1 month. All patients who received at least one study treatment dose were included in the efficacy analysis. This trial is registered with ClinicalTrials.gov, number NCT01011751. FINDINGS Of the 919 men initially enrolled, 311 were randomly assigned to one of the study treatments at 6 months: 102 to venlafaxine, 101 to cyproterone, and 108 to medroxyprogesterone. 309 patients were included in the efficacy analysis, since two were excluded for protocol deviations (one in the cyproterone and one in the medroxyprogesterone group; both were excluded because they were already undergoing treatment with serotonin reuptake inhibitor antidepressants at randomisation). The change in median daily hot-flush score between randomisation and 1 month was -47.2% (IQR -74.3 to -2.5) in the venlafaxine group, -94.5% (-100.0 to -74.5) in the cyproterone group, and -83.7% (-98.9 to -64.3) in the medroxyprogesterone group. The decrease from baseline was significant for all three groups (p<0.0001). Pairwise comparison of treatment groups adjusted by the Bonferroni method confirmed that the decreases in hot-flush score were significantly larger in the cyproterone and medroxyprogesterone groups than in the venlafaxine group, regardless of the interval considered (p<0.0001 in all cases). There was no significant difference between the cyproterone and medroxyprogesterone groups (p>0.2 in all cases). Serious side-effects occurred in four, seven, and five patients in the venlafaxine, cyproterone, and medroxyprogesterone groups, respectively, of which none, one (dyspnoea), and one (urticaria) were considered related to the drug, respectively. INTERPRETATION After 6 months of treatment with leuprorelin, venlafaxine, cyproterone, and medroxyprogesterone proved to be effective in reducing hot flushes. However, the hormonal treatments cyproterone and medroxyprogesterone were significantly more effective than venlafaxine. As cyproterone is a recognised treatment in prostate cancer, and its use could interfere with hormonal therapy, medroxyprogesterone could be considered to be the standard treatment for hot flushes in men undergoing androgen suppression for prostate cancer. FUNDING Takeda Laboratories, Puteaux, France.
Collapse
Affiliation(s)
- Jacques Irani
- Urology Unit, University Hospital, Poitiers, France.
| | | | | | | | | |
Collapse
|
12
|
Sharma P, Wisniewski A, Braga-Basaria M, Xu X, Yep M, Denmeade S, Dobs AS, DeWeese T, Carducci M, Basaria S. Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J Urol 2009; 182:2265-72. [PMID: 19758646 PMCID: PMC3089061 DOI: 10.1016/j.juro.2009.07.030] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2009] [Indexed: 11/16/2022]
Abstract
PURPOSE The profound hypogonadism due to androgen deprivation therapy for prostate cancer results in complications such as sexual dysfunction, poor quality of life, vasomotor symptoms and altered cognition. Since estrogen is associated with cardiovascular risks, phytoestrogens are being increasingly evaluated as a potential treatment for these adverse effects. We evaluated the effects of high dose isoflavones, equivalent to that consumed by Asian populations, on the aforementioned consequences of androgen deprivation therapy. MATERIALS AND METHODS A total of 33 men undergoing androgen deprivation therapy for prostate cancer were enrolled in this randomized, double-blind, placebo controlled, 12-week pilot trial. Participants were randomly assigned to receive 20 gm soy protein containing 160 mg total isoflavones (17) vs taste matched placebo, that is 20 gm whole milk protein (16). The study was performed at a tertiary care center in the United States. RESULTS At baseline the groups were well matched in demographic parameters, sleep quality, cognition and overall quality of life. However, men in the isoflavone group had a higher baseline prevalence of hot flashes and poor intercourse satisfaction compared to those on placebo. At 12 weeks there were no significant differences between the 2 groups in any outcome measure. CONCLUSIONS This pilot study of high dose isoflavones in androgen deprived men showed no significant improvement in cognition, vasomotor symptoms or any other aspect of quality of life measures compared to placebo. Future studies should use variable doses of isoflavones for a longer period before ruling out beneficial isoflavone effects in this population.
Collapse
Affiliation(s)
- Preetika Sharma
- Georgetown University (PS), Washington, D. C., Division of Pediatric Endocrinology, Oklahoma University School of Medicine (AW), Tulsa, Oklahoma, Division of Endocrinology and Metabolism, Boston University School of Medicine (SB), Boston (MBB), Massachusetts, and Divisions of Endocrinology and Metabolism (XX, MY, ASD) and Radiation Oncology (TDW) and Sidney Kimmel Comprehensive Cancer Center (SD, MC), Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Amy Wisniewski
- Georgetown University (PS), Washington, D. C., Division of Pediatric Endocrinology, Oklahoma University School of Medicine (AW), Tulsa, Oklahoma, Division of Endocrinology and Metabolism, Boston University School of Medicine (SB), Boston (MBB), Massachusetts, and Divisions of Endocrinology and Metabolism (XX, MY, ASD) and Radiation Oncology (TDW) and Sidney Kimmel Comprehensive Cancer Center (SD, MC), Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Milena Braga-Basaria
- Georgetown University (PS), Washington, D. C., Division of Pediatric Endocrinology, Oklahoma University School of Medicine (AW), Tulsa, Oklahoma, Division of Endocrinology and Metabolism, Boston University School of Medicine (SB), Boston (MBB), Massachusetts, and Divisions of Endocrinology and Metabolism (XX, MY, ASD) and Radiation Oncology (TDW) and Sidney Kimmel Comprehensive Cancer Center (SD, MC), Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Xiaoqiang Xu
- Georgetown University (PS), Washington, D. C., Division of Pediatric Endocrinology, Oklahoma University School of Medicine (AW), Tulsa, Oklahoma, Division of Endocrinology and Metabolism, Boston University School of Medicine (SB), Boston (MBB), Massachusetts, and Divisions of Endocrinology and Metabolism (XX, MY, ASD) and Radiation Oncology (TDW) and Sidney Kimmel Comprehensive Cancer Center (SD, MC), Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Mary Yep
- Georgetown University (PS), Washington, D. C., Division of Pediatric Endocrinology, Oklahoma University School of Medicine (AW), Tulsa, Oklahoma, Division of Endocrinology and Metabolism, Boston University School of Medicine (SB), Boston (MBB), Massachusetts, and Divisions of Endocrinology and Metabolism (XX, MY, ASD) and Radiation Oncology (TDW) and Sidney Kimmel Comprehensive Cancer Center (SD, MC), Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Samuel Denmeade
- Georgetown University (PS), Washington, D. C., Division of Pediatric Endocrinology, Oklahoma University School of Medicine (AW), Tulsa, Oklahoma, Division of Endocrinology and Metabolism, Boston University School of Medicine (SB), Boston (MBB), Massachusetts, and Divisions of Endocrinology and Metabolism (XX, MY, ASD) and Radiation Oncology (TDW) and Sidney Kimmel Comprehensive Cancer Center (SD, MC), Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Adrian S. Dobs
- Georgetown University (PS), Washington, D. C., Division of Pediatric Endocrinology, Oklahoma University School of Medicine (AW), Tulsa, Oklahoma, Division of Endocrinology and Metabolism, Boston University School of Medicine (SB), Boston (MBB), Massachusetts, and Divisions of Endocrinology and Metabolism (XX, MY, ASD) and Radiation Oncology (TDW) and Sidney Kimmel Comprehensive Cancer Center (SD, MC), Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Theodore DeWeese
- Georgetown University (PS), Washington, D. C., Division of Pediatric Endocrinology, Oklahoma University School of Medicine (AW), Tulsa, Oklahoma, Division of Endocrinology and Metabolism, Boston University School of Medicine (SB), Boston (MBB), Massachusetts, and Divisions of Endocrinology and Metabolism (XX, MY, ASD) and Radiation Oncology (TDW) and Sidney Kimmel Comprehensive Cancer Center (SD, MC), Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Michael Carducci
- Georgetown University (PS), Washington, D. C., Division of Pediatric Endocrinology, Oklahoma University School of Medicine (AW), Tulsa, Oklahoma, Division of Endocrinology and Metabolism, Boston University School of Medicine (SB), Boston (MBB), Massachusetts, and Divisions of Endocrinology and Metabolism (XX, MY, ASD) and Radiation Oncology (TDW) and Sidney Kimmel Comprehensive Cancer Center (SD, MC), Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Shehzad Basaria
- Georgetown University (PS), Washington, D. C., Division of Pediatric Endocrinology, Oklahoma University School of Medicine (AW), Tulsa, Oklahoma, Division of Endocrinology and Metabolism, Boston University School of Medicine (SB), Boston (MBB), Massachusetts, and Divisions of Endocrinology and Metabolism (XX, MY, ASD) and Radiation Oncology (TDW) and Sidney Kimmel Comprehensive Cancer Center (SD, MC), Johns Hopkins University School of Medicine, Baltimore, Maryland
| |
Collapse
|
13
|
Nishimura K, Yamaguchi Y, Yamanaka M, Ichikawa Y, Nagano S. Climacteric-Like Disorders in Prostate Cancer Patients Treated With LHRH Agonists. ACTA ACUST UNITED AC 2009; 51:41-8. [PMID: 15764416 DOI: 10.1080/014850190513003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
We assessed long-term side effects with characteristics of female climacteric disorders in prostate cancer patients treated with luteinizing hormone-releasing hormone (LHRH) agonists. Such side effects are not considered to be serious, though they can significantly affect patient quality of life. Sixty-four prostate cancer patients treated with LHRH agonists and 30 benign prostatic hyperplasia patients, as a control group, were surveyed by questionnaire. The median age of the cancer patients was 74.9 years old, ranging from 60 to 94 years, and the median LHRH agonist dosing period was 16.5 months, ranging from 1 to 64 months. The results of the questionnaires were compared between the patients and the controls, as well as between different variables. Sixty (93.8%) of 64 patients claimed symptoms similar to female climacteric disorders. Further, more than 50% of the symptoms included in the questionnaire were reported by 14 (21.9%) of the patients. Symptoms reported by the patients were more severe than those by the controls. Hot flashes, sleep disturbance, and fatigue recorded high scores in the patient questionnaires as compared with those of the controls. In addition, as the term of LHRH agonist use increased, complaints of sweating or coldness in hands and feet increased. Patients without bone metastasis frequently experienced heaviness in the head and headaches compared to those with bone metastasis. The results of our questionnaire-based outcome study showed that side effects similar to female climacteric disorders in prostate cancer patients treated with LHRH agonists were more severe than in the control group, which could be detrimental to quality of life and general well-being.
Collapse
Affiliation(s)
- K Nishimura
- Department of Urology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan.
| | | | | | | | | |
Collapse
|
14
|
Gupta P, Sturdee DW, Palin SL, Majumder K, Fear R, Marshall T, Paterson I. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric 2009; 9:49-58. [PMID: 16428125 DOI: 10.1080/13697130500487224] [Citation(s) in RCA: 142] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
OBJECTIVES To determine, first, the prevalence and severity of various symptoms related to estrogen deficiency in women within a few years of receiving treatment for breast cancer, second, how women perceive the effects of these symptoms on their quality of life and, third, what measures have been taken to relieve vasomotor symptoms. METHODS Two hundred women (aged 29-65 years) who had received treatment for breast cancer within the last 5 years were included in this cross-sectional survey. Information was collected about their breast cancer treatment, menopausal symptoms (Menopausal Rating Scale), the perceived effects of menopausal symptoms on their and their partner's quality of life and any treatments they were receiving for hot flushes. RESULTS All but one woman reported at least one symptom related to the menopause (95.9% vasomotor; 83.3% psychological; 89.7% somatic). Current treatment with tamoxifen or previous chemotherapy did not influence the prevalence or the severity of hot flushes. Current antidepressant treatment was, however, significantly associated with a higher prevalence and severity of most menopausal symptoms, including hot flushes and sweats (p = 0.008). The severity of hot flushes and sweats was significantly correlated with self-assessed effects on overall quality of life (r(s) = 0.47); 56.4% of the respondents believed that menopausal symptoms had affected their partner's quality of life, the strongest correlations being with severity of sexual symptoms (r(s) = 0.56) and vaginal dryness (r(s) = 0.5). Only 21% of women experiencing hot flushes were receiving any treatment for hot flushes, with most women describing no knowledge or poor knowledge of treatment options. CONCLUSIONS The majority of women receiving treatment for breast cancer report menopausal symptoms, which negatively correlate, not only with their own, but also with their partner's quality of life. Most women experiencing hot flushes are not receiving treatment due to lack of both awareness and confidence in the existing treatment options.
Collapse
Affiliation(s)
- P Gupta
- Women's Unit, Solihull Hospital, Heart of England NHS Foundation Trust, Solihull
| | | | | | | | | | | | | |
Collapse
|
15
|
Lee MS, Kim KH, Shin BC, Choi SM, Ernst E. Acupuncture for treating hot flushes in men with prostate cancer: a systematic review. Support Care Cancer 2009; 17:763-70. [PMID: 19224253 DOI: 10.1007/s00520-009-0589-3] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2008] [Accepted: 01/20/2009] [Indexed: 12/21/2022]
Abstract
GOALS OF WORK The goal of the study was to assess the effects of acupuncture as a treatment for hot flushes in prostate cancer (PC) patients. MATERIALS AND METHODS The literature was searched using 14 databases with dates ranging from their inceptions to December 2008 and without language restrictions. All clinical studies of any type of acupuncture in PC patients were included. Their main outcome measures had to be vasomotor symptoms. Their methodological quality was assessed using the modified Jadad score. RESULTS Six studies met all the inclusion criteria. One randomised clinical trial compared the effects of manual acupuncture with acupuncture plus electro-acupuncture. The other five studies were uncontrolled observational studies and therefore had limitations. CONCLUSION The evidence is not convincing to suggest acupuncture is an effective treatment for hot flush in patients with PC. Further research is required to investigate whether acupuncture has hot-flush-specific effects.
Collapse
Affiliation(s)
- Myeong Soo Lee
- Department of Medical Research, Korea Institute of Oriental Medicine, Daejeon, 305-811, South Korea.
| | | | | | | | | |
Collapse
|
16
|
Paul KN, Turek FW, Kryger MH. Influence of sex on sleep regulatory mechanisms. J Womens Health (Larchmt) 2009; 17:1201-8. [PMID: 18710368 DOI: 10.1089/jwh.2008.0841] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The ability of biological sex and sex-driven characteristics to alter sleep states may contribute to gender disparities in sleep disorders. Sex influences sleep-wake amount, the daily timing of the sleep-wake cycle, and the ability to restore sleep after extended wakefulness. Several lines of evidence suggest that in mammals, reproductive hormones are responsible for the effects of sex on sleep and may have organizational and activational influences on sleep regulatory mechanisms. In humans, exogenously administered estrogens and progestins generally enhance sleep amount and continuity, whereas androgens appear to have a positive impact on rapid eye movement (REM) sleep but disrupt sleep consolidation. In rodent studies, however, female reproductive hormones appear to enhance wakefulness, and male gonadal hormones reinforce sleep. Rodent studies have also revealed that neonatal exposure to reproductive hormones organizes adult sleep-wake architecture. This paper reviews how sex and reproductive hormones interact with circadian and homeostatic sleep regulatory mechanisms in humans and animal models. We examine the organizational and activational nature of these interactions and also review how these interactions change with advancing age. Finally, we discuss the potential for genetic sex to influence sleep states. It is our hope that a better understanding of the mechanisms through which sex influences sleep-wake states will lead to improvements in the design of studies that examine gender disparities in sleep-wake disorders.
Collapse
Affiliation(s)
- Ketema N Paul
- Department of Anatomy and Neurobiology, Morehouse School of Medicine, Atlanta, Georgia 30310-1495, USA.
| | | | | |
Collapse
|
17
|
Revisión del tratamiento actual de los sofocos inducidos por deprivación androgénica en el carcinoma prostático. Actas Urol Esp 2009; 33:337-43. [DOI: 10.1016/s0210-4806(09)74157-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
18
|
Mohile SG, Mustian K, Bylow K, Hall W, Dale W. Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol 2008; 70:235-55. [PMID: 18952456 DOI: 10.1016/j.critrevonc.2008.09.004] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2008] [Revised: 08/12/2008] [Accepted: 09/03/2008] [Indexed: 02/07/2023] Open
Abstract
Prostate cancer is the most common malignancy in older men. With the aging of the population, the number of older men with prostate cancer will grow rapidly. Androgen deprivation therapy (ADT) is the mainstay of treatment for men with systemic disease and is increasingly utilized as primary therapy or in combination with other therapies for localized disease. Side effects of therapy are multifold and include hot flashes, osteoporosis, and adverse psychological and metabolic effects. Recent research has illustrated that ADT can negatively impact the functional, cognitive, and physical performance of older men. Patients with prostate cancer, despite recurrence of the disease, have a long life expectancy and may be subjected to the side effects of ADT for many years. This review highlights the complications of ADT and approaches to management. We also provide recommendations for assessment and management of ADT complications among the most vulnerable and frail older male patients.
Collapse
Affiliation(s)
- Supriya G Mohile
- James Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA.
| | | | | | | | | |
Collapse
|
19
|
Ahmadi A, Mohammadi R, Schwebel DC, Khazaie H. Treating Hot Flashes. Med Acupunct 2008. [DOI: 10.1089/acu.2008.0592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Alireza Ahmadi
- Kermanshah University of Medical Sciences (KUMS), Department of Anesthesiology, Critical Care and Pain Management, Kermanshah University of Medical Sciences, Kermanshah City—Kermanshah Province, 6718818838 IRAN
| | | | | | | |
Collapse
|
20
|
Barton D, Loprinzi CL. Making Sense of the Evidence Regarding Nonhormonal Treatments for Hot Flashes. Clin J Oncol Nurs 2007; 8:39-42. [PMID: 14983762 DOI: 10.1188/04.cjon.39-42] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The demand for nonhormonal interventions for hot flashes is increasing because of the number of patients diagnosed with hormone-sensitive cancers and the results of the Women's Health Initiative indicating that hormone replacement therapy is not as beneficial as originally believed. Since 2002, numerous studies testing nonhormonal treatments for hot flashes have been conducted. Clinicians need to be able to use these research findings to help patients make treatment decisions. Because hot flashes can interfere with activities of daily living such as sleep and work, clinicians first should assess the extent to which hot flashes are disruptive to a woman's life. The evidence for nonhormonal interventions is summarized, and a decision treatment algorithm is offered for use in clinical practice. This algorithm includes nonhormonal options of the antidepressants available in addition to gabapentin, an antiseizure medication. A short review of the evidence for possible complementary therapies also is included.
Collapse
|
21
|
Abstract
Because many patients who have biochemical relapse will live for many years,preventing additional morbidity in those who are treated with ADT is of the utmost importance. No standard therapy is currently available for men who have biochemical relapse, although data are beginning to show that earlierADT may result in improved survival, at least in patients who have somewhat more advanced disease or rapid PSA doubling times or velocities. Treatment with intermittent ADT may attenuate some of the morbidities, such as loss of bone mineral density. Not all patients will experience all or even many of these complications, but patients can be empowered by learning about these beforehand and under-standing what can be done to prevent, monitor, or treat the side effects. Table 2 summarizes recommendations for baseline evaluations of men prior to initiation of ADT, and Table 3 summarizes interventions for specific complications. Better markers to distinguish patients who will benefit from ADT are needed. Newer hormonal agents or supplements are being researched. In the meantime, patients and the health care team can work together to combat complications related to ADT.
Collapse
Affiliation(s)
- Celestia Higano
- Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA.
| |
Collapse
|
22
|
Affiliation(s)
- Kevin M O'Connor
- Department of Surgery, Mater Misericordiae University Hospital, University College Dublin, Ireland.
| | | |
Collapse
|
23
|
Carpenter JS, Neal JG. Other complementary and alternative medicine modalities: acupuncture, magnets, reflexology, and homeopathy. Am J Med 2005; 118 Suppl 12B:109-17. [PMID: 16414335 DOI: 10.1016/j.amjmed.2005.09.058] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We sought to evaluate evidence for the benefits and risks of acupuncture, magnets, reflexology, and homeopathy for menopause-related symptoms. Search strategies included electronic searches of online databases (PubMed, PsycINFO, Medline), direct searches of target journals, and citation-index searches. A total of 12 intervention studies were identified for review. Complementary and alternative medicine (CAM) treatments resulted in few side effects. The design, study populations, and findings across acupuncture studies varied. In uncontrolled studies, acupuncture improved subjective measures of hot flash frequency and vasomotor, somatic, physical, and psychological symptoms; however, improvements were not consistent. Controlled studies of acupuncture yielded even less consistent findings. Overall, controlled studies of acupuncture did not reliably improve hot flashes, sleep disturbances, or mood when compared with nonspecific acupuncture, estrogen therapy, or superficial needling. Homeopathy significantly improved subjective measures of hot flash frequency and severity, mood, fatigue, and anxiety in uncontrolled, open-label studies. Controlled studies of magnets and reflexology failed to demonstrate any increased benefit of treatment over placebo. There is a need for additional investigations of acupuncture and homeopathy for the treatment of hot flashes and other menopausal symptoms. However, existing evidence does not indicate a beneficial effect of magnets or reflexology in the treatment of hot flashes and other menopausal symptoms. Understanding whether, for whom, and how these interventions work is crucial to building the evidence base needed to evaluate any potential for these CAM therapies in the management of menopause-related symptoms.
Collapse
Affiliation(s)
- Janet S Carpenter
- School of Nursing, Indiana University, Indianapolis, Indiana 46202, USA.
| | | |
Collapse
|
24
|
Cohen AJ, Menter A, Hale L. Acupuncture: role in comprehensive cancer care--a primer for the oncologist and review of the literature. Integr Cancer Ther 2005; 4:131-43. [PMID: 15911926 DOI: 10.1177/1534735405276419] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
In recent studies, patients have reported an increased use of complementary and alternative medicine (CAM). Acupuncture is a popular complementary therapy for patients with cancer. This article will provide current cancer treatment providers with information on acupuncture as well as the research conducted on cancer symptoms and side effects of cancer treatments. Antiemetic studies are the most prevalent and contain the most promising results. Several studies have found that acupuncture significantly reduces the number of emesis (vomiting) episodes for patients receiving chemotherapy. While studies on pain control vary due to the heterogeneity of pain, there are few studies investigating pain caused from cancer and the removal of cancerous tumors. These studies, while promising, provide basic results that need further investigation for more definitive results. Although relatively few studies have been done on anxiety and depression, several researchers have found acupuncture to be just as effective as or more effective than antidepressants for patients without cancer. Studies on breathlessness, while small, have shown acupuncture to have a significant positive effect on chronic obstructive pulmonary disease, breathlessness associated with end-stage cancer, and asthma. Researchers studying xerostomic individuals who have received salivary gland irradiation found significant positive results in salivary flow rates compared to baseline. Patients with hot flashes due to hormonal imbalance may benefit from the use of acupuncture. A recent pilot study showed improvement of chronic postchemotherapy fatigue following acupuncture treatments. Many individuals with cancer have turned to acupuncture because their symptoms persisted with conventional treatments or as an alternative or complement to their ongoing treatments. Despite the immense popularity in the community, few large randomized trials have been conducted to determine the effects acupuncture has on cancer symptoms and side effects of treatments. A majority of the current studies have shown beneficial effects that warrant further investigation with large trial sizes.
Collapse
Affiliation(s)
- Andrea J Cohen
- Division of Pulmonary Sciences and Critical Care Medicine, Division of Medical Oncology, University of Colorado Health Sciences Center, University of Colorado Cancer Center, Denver, CO 80262, USA.
| | | | | |
Collapse
|
25
|
Moyad MA. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol Oncol 2005; 23:56-64. [PMID: 15885584 DOI: 10.1016/j.urolonc.2005.03.018] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Androgen deprivation for prostate cancer use to be applied only in the latter stage of the disease process, thus, the issue of promoting general health during this time was not a concern because the subject of life and death was more paramount. However, thanks to earlier detection of prostate cancer, there has been a general stage migration in this disease. Men are choosing these traditionally late stage therapies earlier and earlier. Therefore, the subject of quality of life on this treatment has now garnered as much attention as the survival issues. Cognitive or mental health concerns, cholesterol changes, hot flashes, osteoporosis, and other side effects are being addressed and treated with a variety of conventional medicines. However, the issue of the role of the patient or what men can do personally to promote better mental and physical health is desperately needed in this area. A variety of beneficial lifestyle changes and over-the-counter agents may have an enormous impact on men's health during androgen deprivation. Calcium and vitamin D supplements, aerobic and resistance exercise, cholesterol awareness and reduction, weight loss, and other individual changes could have an enormous impact on the quality and quantity of a man's life. Some of these so called "bottom line" recommendations are reviewed in this article to empower the patient during this time, and to send clearly the message that he has a role to play apart from just picking up and using a prescription drug for side effects, and his role is just as critical for improving the probability of living longer and better.
Collapse
Affiliation(s)
- Mark A Moyad
- Phil F. Jenkins Director of Complementary & Alternative Medicine, Department of Urology, University of Michigan Medical Center, Ann Arbor, 48109-0330, USA.
| |
Collapse
|
26
|
Carpenter JS. State of the science: hot flashes and cancer. Part 2: management and future directions. Oncol Nurs Forum 2005; 32:969-78. [PMID: 16136195 DOI: 10.1188/05.onf.969-978] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
PURPOSE/OBJECTIVES To critically evaluate and synthesize intervention research related to hot flashes in the context of cancer and to identify implications and future directions for policy, research, and practice. DATA SOURCES Published, peer-reviewed articles and textbooks; editorials; and computerized databases. DATA SYNTHESIS Although a variety of pharmacologic and nonpharmacologic treatments are available, they may not be appropriate or effective for all individuals. CONCLUSIONS The large and diverse evidence base and current national attention on hot flash treatment highlight the importance of the symptom to healthcare professionals, including oncology nurses. IMPLICATIONS FOR NURSING Using existing research to understand, assess, and manage hot flashes in the context of cancer can prevent patient discomfort and improve the delivery of evidence-based care.
Collapse
|
27
|
Abstract
Hormonal manipulation in the form of androgen-deprivation therapy for prostate cancer was introduced by Huggins and Hodges in 1941 and resulted in a Nobel Prize in 1966. Hormonal therapy initially had been used in metastatic prostate cancer, but the indications have been expanded including failed local therapy, locally advanced prostate cancer, and neoadjuvant or adjuvant therapy in high-risk localized prostate cancer. In view of the magnitude of the problem of prostate cancer and relatively frequent use of hormonal manipulation, it is important for clinicians to be aware of common side effects, prevention, and treatment to improve quality of life and reduce morbidity and mortality in patients with prostate cancer. This review focuses on the common side effects of hormonal treatment such as osteoporosis, anemia, hot flashes, erectile dysfunction, muscle wasting, gynecomastia, decline in cognitive function, depression, increase in body fat and metabolic changes, and their prevention and treatment.
Collapse
Affiliation(s)
- Ravi J Kumar
- Urologic Oncology, University of Colorado Health Sciences Center, 4200 East 9th Avenue C-319, Denver, CO 80262, USA.
| | | | | |
Collapse
|
28
|
Abstract
Micronutrient and herbal/phytochemical supplements are of increasing interest as potential alternatives to using estrogen therapy in treating menopausal symptoms. This article provides an overview of the questionnaires that assess menopausal symptoms and research efforts to better standardize symptom assessment. The reported rate of symptoms varies by ethnicity, stage of menopause, hormonal therapy and the measurement method. The use of estrogen therapy has declined sharply after the Women's Health Initiative (WHI) Hormone Trial was stopped early because the potential risks outweighed potential benefits. There is a limited research base that addresses the efficacy of supplements in controlling menopausal symptoms. The generalizability of several studies is limited because the study participants experiences menopause as the results of treatment for breast cancer. The article concludes with a review of guidelines and of issues that need to be addressed in future research studies with emphasis on questions related to clinical practice.
Collapse
Affiliation(s)
- Judith Wylie-Rosett
- Division of Health, Behavior and Nutrition, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
| |
Collapse
|
29
|
Beck V, Rohr U, Jungbauer A. Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy? J Steroid Biochem Mol Biol 2005; 94:499-518. [PMID: 15876415 DOI: 10.1016/j.jsbmb.2004.12.038] [Citation(s) in RCA: 164] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2003] [Accepted: 12/14/2004] [Indexed: 11/21/2022]
Abstract
The benefits of plant extracts from soy and red clover as alternatives to conventional hormone replacement therapy (HRT) have been debated in the past. Here, an attempt has been made to summarize the biochemical and pharmacological data in the light of clinical aspects. Red clover and soy extracts contain isoflavones, which have a high affinity to estrogen receptor alpha (ERalpha), estrogen receptor beta (ERbeta), progesterone receptor (PR) and androgen receptor (AR). The higher affinity to ERbeta compared to ERalpha has been used as an explanation why red clover extracts function as food additives to treat menopausal disorders and may reduce risk of breast cancer. Biochemical analysis shows that these representatives of phytoestrogens have multiple actions beside selective estrogen receptor modulator (SERM)-activity. They act as selective estrogen enzyme modulators (SEEMs), have antioxidant activity and interact with transcription factors such as NF-kappaB. Furthermore, it is indicated that they have protective effects on osteoporosis and the cardiovascular system. Currently 40-50mg of isoflavones (biochanin A, daidzein, formononetin and genistein) are recommended as daily dose. This recommendation is based on the daily intake of phytoestrogens in a traditional Japanese diet.
Collapse
Affiliation(s)
- V Beck
- Department of Biotechnology, University of Natural Resources and Applied Life Sciences, Muthgasse 18, 1190 Vienna, Austria
| | | | | |
Collapse
|
30
|
Nishiyama T, Kanazawa S, Watanabe R, Terunuma M, Takahashi K. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol 2004; 11:735-41. [PMID: 15379937 DOI: 10.1111/j.1442-2042.2004.00896.x] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND We surveyed patients with prostate cancer treated with androgen deprivation therapy to examine the influence of hot flashes on quality of life (QOL). METHODS Fifty-five outpatients with prostate cancer (M0, 39; M1, 16) treated with androgen deprivation therapy (castration, 15; castration and antiandrogen, 40) were enrolled in this study. Mean duration of androgen deprivation therapy was 21 months (2-91 months). The patients were still being treated with androgen deprivation therapy at the time of the survey. The functional assessment of cancer therapy (FACT) was used as a QOL questionnaire for outpatients with prostate cancer treated with androgen deprivation therapy. Hot flash assessments were used to document the number and severity (mild, moderate, and severe) of daily hot flashes. The patients prescribed fluvoxamine maleate were reassessed for hot flashes 2 weeks after the prescription. RESULTS Thirty-two of the 55 patients (58.2%) suffered from hot flashes. Hot flashes deteriorated the physical well-being subscale of QOL in patients with prostate cancer treated with androgen deprivation therapy (P = 0.043). There was a significant relationship between the desire to be treated for hot flashes and the hot flash assessments (P = 0.038). Fluvoxamine maleate was significantly effective in reducing hot flashes (P = 0.001). CONCLUSIONS Hot flashes had adverse effects on the patients' physical status and deteriorated the patients' QOL. New treatment options such as fluvoxamine maleate might help simplify the often difficult management of hot flashes in patients with prostate cancer treated with androgen deprivation therapy.
Collapse
Affiliation(s)
- Tsutomu Nishiyama
- Division of Urology, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Asahimachi 1-757, Niigata 951-8510, Japan.
| | | | | | | | | |
Collapse
|
31
|
Elek T, Reich M. Place des antidépresseurs sérotoninergiques dans la prise en charge des bouffées de chaleur en cancérologie. Rev Med Interne 2004; 25:217-24. [PMID: 15049283 DOI: 10.1016/j.revmed.2003.11.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
INTRODUCTION Menopausal women or patients treated by chemotherapy or hormonotherapy for breast cancer have often disabled hot flashes. Men with prostate cancer confronted to castration can also suffer from the same problem. In both situations, many arguments go against implementation of estrogenic treatment. Albeit, many complementary therapeutics exist, they are often unsatisfying. CURRENT KNOWLEDGE AND KEY POINTS Since some years, anecdotal case reports and controlled studies have reported interest of selective serotonin reuptake inhibitors (SSRIs) antidepressants in this indication. These treatments often appear efficient and well tolerated. FUTURE AND PROJECTS Through a review of literature and clinical vignette, we will specify physiopathology and prescription modalities in this new type of indication.
Collapse
Affiliation(s)
- T Elek
- Unité de psycho-oncologie, centre Oscar-Lambret, Lille, France
| | | |
Collapse
|
32
|
Hunter MS, Grunfeld EA, Mittal S, Sikka P, Ramirez AJ, Fentiman I, Hamed H. Menopausal symptoms in women with breast cancer: Prevalence and treatment preferences. Psychooncology 2004; 13:769-78. [PMID: 15386641 DOI: 10.1002/pon.793] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Menopausal symptoms are common and problematic for women receiving adjuvant treatment for breast cancer and management presents a challenge. This cross-sectional descriptive study aimed to investigate the experience of menopausal symptoms, current management and treatment preferences of 113 patients with breast cancer. These women (who were prescribed tamoxifen and were on average 3 years post-diagnosis) were recruited from a breast unit database. They completed the Hot Flush and Night Sweats Questionnaire (HFNSQ), the Women's Health Questionnaire (WHQ) and subscales of the EORTC-QLQ-C30 and the BR23, as well as questions about treatments. Forty-four of this sample were also interviewed. The prevalence of hot flushes and night sweats was 80 and 72%, respectively (average 30 per week). Having more problematic hot flushes and night sweats were associated with more anxiety and sleep problems (WHQ), and with poorer emotional and social functioning and worse body image (EORTC-QLQ-C30). The women had used a range of treatments for menopausal symptoms but there was often no evidence for the efficacy for many of these treatments. Strongest preferences were for non-medical treatments, particularly vitamins and herbal remedies and cognitive behavioural therapy (CBT). The evidence for the effectiveness of the former is weak, whereas CBT has been shown to reduce menopausal symptoms, but needs to be evaluated in a population of women who have been treated for breast cancer.
Collapse
Affiliation(s)
- Myra S Hunter
- Cancer Research UK London Psychosocial Group, Institute of Psychiatry, King's College London, UK.
| | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
Phytoestrogens are a diverse group of plant-derived compounds that structurally or functionally mimic mammalian estrogens and show potential benefits for human health. The number of articles published on phytoestrogens has risen dramatically in the past couple decades. Further research continues to demonstrate the biological complexity of phytoestrogens, which belong to several different chemical classes and act through diverse mechanisms. This paper discusses the classification of phytoestrogens, methods of identification, their proposed mechanisms of action and botanical sources for phytoestrogens. The effects of phytoestrogens on breast and prostate cancers, cardiovascular disease, menopausal symptoms and osteoporosis will also be examined including research on benefits and risks.
Collapse
Affiliation(s)
- Andreana L Ososki
- Biological Sciences, Lehman College, City University of New York, 250 Bedford Park Blvd West, Bronx, NY 10468, USA
| | | |
Collapse
|
34
|
Hunter M. Cognitive behavioural interventions for premenstrual and menopausal symptoms. J Reprod Infant Psychol 2003. [DOI: 10.1080/0264683031000155006] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
35
|
Nieman LK. Management of surgically hypogonadal patients unable to take sex hormone replacement therapy. Endocrinol Metab Clin North Am 2003; 32:325-36. [PMID: 12800534 DOI: 10.1016/s0889-8529(03)00011-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Lifestyle changes in diet, exercise and the environment may help to prevent or ameliorate hot flashes and low bone density in men and women after surgical castration. Conventional medications, including megestrol acetate, SSRIs or clonidine, may improve hot flashes but may have limiting side effects. Some complementary and alternative approaches, including black cohosh, vitamin E, and soy products, work as well as placebo to decrease hot flashes and may be helpful, because they have low toxicity. Acupuncture and neurontin are promising but must be studied further. With regards to the prevention of osteoporosis and fractures in men and women, bisphosphonates are the most potent of the currently available agents; calcitonin is less effective. PTH has a large beneficial effect but is not yet available and is less well studied. In women, continued sexual intercourse and use of vaginal lubricants and moisturizers help to minimize symptoms of vaginal atrophy but do not ameliorate urinary symptoms. Low dose local estrogen treatment is a promising approach for the latter complaints.
Collapse
Affiliation(s)
- Lynnette K Nieman
- Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Building 10, Room 9D42 MSC 1583, 10 Center Drive, Bethesda, MD 20892, USA.
| |
Collapse
|
36
|
Abstract
The current trends in favor of androgen deprivation therapy (ADT) for nonmetastatic prostate cancer at the stage of biochemical recurrence or increasing prostate-specific antigen (PSA) raises the issue of exposing otherwise asymptomatic patients to potential side effects over the longer term. Some of these side effects can have deleterious effects on quality of life, and others may contribute to increased risks for serious health concerns associated with aging. Sexual side effects are the most well-recognized adverse effects from ADT and include loss of libido, erectile dysfunction (ED), and hot flashes. Loss of libido is distressing to many men, and they may not pursue treatments for ED. However, for those who do maintain sexual interest, various remedies are available. The incidence of hot flashes, which may not abate over the course of ADT, is close to 80%. Estrogens, progestin megestrol acetate, medroxyprogesterone acetate, venlafaxine, and cyproterone acetate have been shown to alleviate hot flashes and associated symptoms. Physiologic effects, including gynecomastia, changes in body composition (weight gain, reduced muscle mass, increase in body fat), and changes in lipids, are less commonly recognized as side effects of ADT. These may lead to an exacerbation of potentially more serious conditions, such as hypertension, diabetes, and coronary artery disease. Loss of bone mineral density, anemia, and hair changes also may occur. Additionally, both the diagnosis of prostate cancer and the hormonal therapy can cause psychological distress. These side effects need more systematic study in clinical trials. Physicians should be aware of far-reaching consequences of ADT and should incorporate strategies for preventing and managing toxicities into routine practice.
Collapse
Affiliation(s)
- Celestia S Higano
- Department of Urology, University of Washington School of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, Washington 98109, USA.
| |
Collapse
|
37
|
Pucci V, Bugamelli F, Mandrioli R, Luppi B, Raggi MA. Determination of progesterone in commercial formulations and in non conventional micellar systems. J Pharm Biomed Anal 2003; 30:1549-59. [PMID: 12467927 DOI: 10.1016/s0731-7085(02)00547-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Progesterone was determined in commercial pharmaceutical formulations and experimental micellar systems by means of two analytical methods based on liquid chromatography and derivative spectrophotometry. The chromatographic analysis, with ultraviolet detection at 245 nm, was carried out on a C8 column using a mobile phase composed of 2-propanol and a pH 2.5, 30 mM phosphate buffer. Derivative spectrophotometry (DS) used the difference between the values of the first derivative at 227.2 and 253.6 nm. Both methods require only a simple extraction procedure of progesterone from the formulations before analysis. The high-performance liquid chromatography (HPLC) procedure allows for the quantitative determination of progesterone in all pharmaceutical formulations tested (oily and alcoholic injectable solutions, gel preparations and soft capsules) and also of the newly-developed polymeric micellar system. On the contrary, the derivative spectrophotometric method is not suitable for the pharmaceutical formulation containing estradiol and for the new micellar systems. The results obtained with the two methods are in good agreement and always satisfactory in terms of precision and accuracy.
Collapse
Affiliation(s)
- Vincenzo Pucci
- Department of Pharmaceutical Sciences, University of Bologna, Via Belmeloro 6, Bologna, Italy
| | | | | | | | | |
Collapse
|
38
|
Patterson SG, Balducci L, Pow-Sang JM. Controversies surrounding androgen deprivation for prostate cancer. Cancer Control 2002; 9:315-25. [PMID: 12228757 DOI: 10.1177/107327480200900406] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Management of metastatic prostate cancer continues to evolve. The widespread use of the prostate-specific antigen (PSA) assay has led to earlier diagnosis and earlier detection of recurrent disease. Debates continue regarding the proper use and timing of endocrine therapy with orchiectomy, estrogen agonists, luteinizing hormone-releasing hormone (LHRH) analogs, LHRH antagonists, and androgen antagonists. METHODS The authors reviewed the significant published materials of the last 20 years that have shaped hormonal management of metastatic and progressive prostate cancer. Major areas of controversy were also identified. RESULTS The present approach to hormonal management is summarized. Five potential pathways to the development of androgen-independent prostate cancer are described. Controversial topics of hormonal management, including immediate vs delayed hormonal therapy, monotherapy vs maximal androgen blockade (MAB), and intermittent hormonal therapy, are discussed. CONCLUSIONS Orchiectomy, estrogen agonists, and LHRH analogs have therapeutic equivalence. Patients who have a rising PSA after definitive treatment for prostate cancer and high risk of recurrent disease may warrant early androgen deprivation. MAB does not appear to be significantly better than single-agent LHRH analog therapy. Intermittent therapy may delay emergence of androgen independence and maintain or improve quality of life.
Collapse
Affiliation(s)
- Stephen G Patterson
- Genitourinary Oncology Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
| | | | | |
Collapse
|